학술논문
Ponatinib is not transported by ABCB1, ABCG2 or OCT-1 in CML cells
Document Type
Letter to the editor
Report
Report
Author
Source
Leukemia. August 1, 2015, p1792, 3 p.
Subject
Language
English
ISSN
0887-6924
Abstract
The third-generation tyrosine kinase inhibitor (TKI) ponatinib (Iclusig) was designed to target native and mutant isoforms of Bcr-Abl, including [Bcr-Abl.sup.T315I]. It was approved for the treatment of CML patients with [...]